(Q34044905)

English

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia (English)

1 reference

Europe PubMed Central

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

30 July 2017

Giovanni Martinelli

2

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

30 July 2017

Aristoteles A N Giagounidis

14

object named as

Aristoteles Giagounidis

1 reference

Europe PubMed Central

30 July 2017

Jacques-Olivier Bay

6

object named as

Jacques-Olivier Bay

1 reference

Europe PubMed Central

30 July 2017

author name string

Elias J Jabbour

3

1 reference

Europe PubMed Central

30 July 2017

Alfonso Quintás-Cardama

4

1 reference

Europe PubMed Central

30 July 2017

Kiyoshi Ando

5

1 reference

Europe PubMed Central

30 July 2017

Andrew Wei

7

1 reference

Europe PubMed Central

30 July 2017

Stefanie Gröpper

8

1 reference

Europe PubMed Central

30 July 2017

Cristina Papayannidis

9

1 reference

Europe PubMed Central

30 July 2017

Kate Owen

10

1 reference

Europe PubMed Central

30 July 2017

Laura Pike

11

1 reference

Europe PubMed Central

30 July 2017

Nicola Schmitt

12

1 reference

Europe PubMed Central

30 July 2017

Paul K Stockman

13

1 reference

Europe PubMed Central

30 July 2017

SPARK-AML1 Investigators

15

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

19 April 2013

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

119

1 reference

Europe PubMed Central

30 July 2017

14

1 reference

Europe PubMed Central

30 July 2017

2611-2619

1 reference

Europe PubMed Central

30 July 2017

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

The treatment of elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Independent prognostic factors for AML outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Prognostic factors in elderly patients with AML and the implications for treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Aurora kinases link chromosome segregation and cell division to cancer susceptibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Validity and reliability of the FACT-G scale for use in the older person with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Gene expression profiling of pediatric acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/23605952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23605952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23605952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28113

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34044905&oldid=1539611248"